Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects―A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 …
Background: There are concerns that Asian patients respond differently to some
medications. This study evaluated the efficacy and safety of evolocumab among Asian vs …
medications. This study evaluated the efficacy and safety of evolocumab among Asian vs …
Retargeting the management of hypercholesterolemia–focus on evolocumab
A Colletti, G Derosa, AFG Cicero - Therapeutics and Clinical Risk …, 2016 - Taylor & Francis
Hypercholesterolemia is one of the main risk factors for atherosclerosis and cardiovascular
diseases. The treatment is based on the modification of the diet and lifestyle and if …
diseases. The treatment is based on the modification of the diet and lifestyle and if …
Safety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145)
MJ Koren, D Blom, RP Giugliano, E Stroes… - Circulation, 2014 - Am Heart Assoc
Introduction: Evolocumab (AMG 145), a fully human monoclonal antibody to proprotein
convertase subtilisin-kexin type 9 (PCSK9), can reduce LDL-C to very low levels, particularly …
convertase subtilisin-kexin type 9 (PCSK9), can reduce LDL-C to very low levels, particularly …
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: Results from the phase III yukawa 2 study
A Kiyosue, N Honarpour, A Xue, S Wasserman… - Journal of the American …, 2015 - jacc.org
Background: Evolocumab (AMG 145), a fully human monoclonal antibody inhibiting PCSK9,
significantly reduced LDL-C in phase 2 and 3 studies. This phase 3 study (the largest …
significantly reduced LDL-C in phase 2 and 3 studies. This phase 3 study (the largest …
Cost-effectiveness of Evolocumab in Adult patients with atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
W Xie, Y Song, X Qin, P Jin - Advances in Therapy, 2023 - Springer
Introduction To assess the cost-effectiveness of evolocumab with statins versus placebo
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …
Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
P Lindgren, E Hagstrom, B Van Hout, G Villa… - European Heart …, 2019 - academia.edu
Background/Introduction: Elevated low-density lipoprotein cholesterol (LDL-C) is one of the
most important modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) …
most important modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) …
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long …
MJ Koren, RP Giugliano, FJ Raal, D Sullivan… - Circulation, 2014 - Am Heart Assoc
Background—Evolocumab (AMG 145), a monoclonal antibody against proprotein
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
EFFECT OF LONGER-TERM ADMINISTRATION OF EVOLOCUMAB IN PATIENTS WITH ANGIOGRAPHIC CORONARY ARTERY DISEASE: RESULTS OF THE …
SJ Nicholls, T Anderson, CM Ballantyne, L Cho… - Journal of the American …, 2020 - jacc.org
Background The GLAGOV study demonstrated that addition of evolocumab to existing
optimal statin therapy produced intensive lowering of low-density lipoprotein cholesterol …
optimal statin therapy produced intensive lowering of low-density lipoprotein cholesterol …